A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 27 May 2017
At a glance
- Drugs Ipilimumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 03 Mar 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Feb 2018.
- 23 Nov 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 15 Oct 2015 Study design was changed to randomized, as 2 treatment arms were included, according to ClinicalTrials.gov record.